Blog
RSS FeedPosted by Michael Wonder on 19 Nov 2019
Lung cancer and leukaemia treatments to be added to PBS
19 November 2019 - “Game changing” drugs for types of lung cancer and leukaemia will be added to the Pharmaceutical Benefits ...
Posted by Michael Wonder on 18 Nov 2019
FDA approves Pfizer's biosimilar, Abrilada (adalimumab-afzb) for multiple inflammatory conditions
18 November 2019 - Pfizer today announced the United States FDA has approved Abrilada (adalimumab-afzb), as a biosimilar to Humira ...
Posted by Michael Wonder on 18 Nov 2019
Improving transparency in decision models: current issues and potential solutions
23 October 2019 - Decision-analytic models have become an essential tool used to inform health technology assessments. ...
Posted by Michael Wonder on 18 Nov 2019
NICE, in confidence: an assessment of redaction to obscure confidential information in single technology appraisals by the National Institute for Health and Care Excellence
17 November 2019 - Health technology assessment aims to provide a transparent framework within which normative judgements can be applied for ...
Posted by Michael Wonder on 18 Nov 2019
Statement from Sarah Yim, acting director of the Office of Therapeutic Biologics and Biosimilars in the FDA’s Center for Drug Evaluation and Research, on FDA’s continued progress facilitating competition in the biologic marketplace with approval of 25th biosimilar product
15 November 2019 - Biological products play an increasingly central role in modern medicine, offering treatments for many serious illnesses. ...
Posted by Michael Wonder on 18 Nov 2019
Biostatistics: a fundamental discipline at the core of modern health data science
28 October 2019 - The value of our health and medical research investment is at risk unless we foster the discipline ...
Posted by Michael Wonder on 18 Nov 2019
Picturing ELSI+: a visual representation of ethical, legal, and social issues, and patient experiences in health technology assessment in Canada
15 November 2019 - Consideration of ethical, legal, and social issues plus patient values (ELSI+) in health technology assessment is challenging ...
Posted by Michael Wonder on 18 Nov 2019
'This drug saved my life;' cystic fibrosis patient accuses drug company, Canada of stalling on approval
17 November 2019 - A West Island woman living with cystic fibrosis says the prohibitive price of a drug is ...
Posted by Michael Wonder on 17 Nov 2019
Tricida announces FDA acceptance of new drug application for veverimer
14 November 2019 - Tricida announced today that the U.S. FDA has accepted for review its new drug application for ...
Posted by Michael Wonder on 17 Nov 2019
CHMP recommends EU approval of Roche’s Kadcyla for the adjuvant treatment of people with HER2-positive early breast cancer with residual invasive disease after neo-adjuvant treatment
15 November 2019 - Kadcyla cut the risk of disease recurrence or death by half compared to Herceptin in the adjuvant ...
Posted by Michael Wonder on 17 Nov 2019
CHMP recommends conditional EU approval of Roche’s Polivy for people with previously treated aggressive lymphoma
15 November 2019 - First-in-class antibody-drug conjugate that specifically targets CD79b, a protein expressed in the majority of B-cells. ...
Posted by Michael Wonder on 16 Nov 2019
Labour will exclude the NHS and medicines from trade deals with the US
17 November 2019 - Donald Trump wants the big US pharmaceutical companies to get its hands on our public services – ...
Posted by Michael Wonder on 16 Nov 2019
Booker and Sanders propose a new federal agency to set drug prices
15 November 2019 - Senators Cory Booker and Bernie Sanders are pushing for the creation of a new federal agency ...
Posted by Michael Wonder on 16 Nov 2019
PBAC Public Summary Documents - July 2019 meeting
15 November 2019 - The Public Summary Documents (first time rejections and deferrals) from the July 2019 PBAC meeting are now ...
Posted by Michael Wonder on 16 Nov 2019
Novartis receives positive CHMP opinion for Mayzent (siponimod) for the treatment of adult patients with active secondary progressive multiple sclerosis
15 November 2019 - If approved, Mayzent (siponimod) will be the first and only oral treatment specifically indicated for patients ...
Posted by Michael Wonder on 15 Nov 2019
Highlights from the CHMP 11-14 November 2019 meeting
15 November 2019 - Seven new medicines recommended for approval. ...